| budesonide/formoterol / Generic mfg. |
NCT00242411 / 2004-000679-32: MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults |
|
|
| Completed | 4 | 1900 | Europe | Budesonide/Formoterol Turbuhaler, Conventional Best Asthma Therapy | AstraZeneca | Asthma | 10/06 | 10/06 | | |
| Completed | 4 | 660 | Canada, Europe, RoW | Symbicort (budesonide/formoterol turbuhaler 320/9ug), Spiriva (tiotropium bromide 18ug) | AstraZeneca | Chronic Obstructive Pulmonary Disease, COPD | 06/08 | 06/08 | | |
SPEED, NCT00542880 / 2007-001337-34: Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide® |
|
|
| Completed | 4 | 442 | Europe, RoW | Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg, Seretide Diskus (salmeterol/fluticasone) 50/500 μg | AstraZeneca | Chronic Obstructive Pulmonary Disease (COPD) | 08/08 | 08/08 | | |
| Completed | 4 | 311 | US | Budesonide / formoterol fumarate (SYMBICORT), SYMBICORT, Budesonide, PULMICORT | AstraZeneca | Asthma | 09/09 | 09/09 | | |
SMARTASIA, NCT00939341: Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia |
|
|
| Completed | 4 | 862 | RoW | Symbicort (Budesonide/Formoterol), Symbicort | AstraZeneca | Asthma | 08/10 | 08/10 | | |
| Completed | 4 | 10 | Europe | Symbicort® forte Turbohaler® | University Hospital, Antwerp, AstraZeneca | Chronic Obstructive Pulmonary Disease | 11/10 | 01/11 | | |
NCT01647646: Real Life Effectiveness in Patients With Not Optimally Controlled Asthma |
|
|
| Completed | 4 | 200 | RoW | Seretide, Symbicort compared with Seretide | Far Eastern Memorial Hospital | Asthma | 02/11 | 03/12 | | |
AZCO, NCT01760304: Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo |
|
|
| Terminated | 4 | 5 | US | Budesonide / Formoterol, Symbicort ®, Placebo | Brigham and Women's Hospital, AstraZeneca | Chronic Obstructive Pulmonary Disease (COPD) | 07/12 | 10/12 | | |
NCT01712854: Effects of Symbicort on the Ventilatory Kinematics |
|
|
| Terminated | 4 | 9 | US | Budesonide, Symbicort | Columbia University, AstraZeneca | Chronic Obstructive Lung Disease | 09/12 | 09/12 | | |
SECURE 1, NCT01397890: Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) |
|
|
| Completed | 4 | 793 | RoW | Budesonide/formoterol (Symbicort® Turbuhaler®), Tiotropium (SpirivaTM) | AstraZeneca | Chronic Obstructive Pulmonary Disease (COPD) | 06/13 | 06/13 | | |
NCT01769898: The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis |
|
|
| Completed | 4 | 50 | RoW | Formoterol-budesonide, Symbicort tu rbuhaler, Theophylline, Theophylline Sustained-Release Tablet, Placebo | The First Affiliated Hospital of Guangzhou Medical University | Bronchiectasis | 09/14 | 11/14 | | |
NCT02233803: A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma |
|
|
| Completed | 4 | 239 | RoW | NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler, SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler, NEUMOTEX 400 (Budesonide 400 mcg), Salbutamol 100 mcg pMDI | GlaxoSmithKline | Asthma | 12/15 | 12/15 | | |
